ABACAVIR/LAMIVUDINA SANDOZ 600mg / 300mg film-coated tablets medication leaflet

J05AR02 • abacavir + lamivudine • Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations

Abacavir and lamivudine are antiretroviral medications used in combination for the treatment of HIV-1 (human immunodeficiency virus) infection. They belong to the class of nucleoside reverse transcriptase inhibitors (NRTIs), working by blocking the reverse transcriptase enzyme, which is essential for HIV replication.

This combination is used as part of antiretroviral therapy (ART) to reduce viral load, increase CD4 cell count, and slow the progression of the disease. It is crucial to take the medication as prescribed, without interruptions, to prevent the development of viral resistance.

Side effects may include nausea, fatigue, headaches, or, more rarely, hypersensitivity reactions to abacavir, which can be severe and require immediate discontinuation of treatment. Genetic testing for the HLA-B*5701 allele is recommended before starting therapy, as its presence is associated with an increased risk of allergic reactions to abacavir.

This combination is effective in managing HIV infection but does not cure the disease. Patients must adhere to long-term treatment and maintain regular health monitoring.